PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lexeo

Lexeo Reports Initial Expression and Biomarker Data of LX1001 in P-I/II Clinical Trial for the Treatment of Alzheimer’s Disease

Lexeo Reports Initial Expression and Biomarker Data of LX1001 in P-I/II Clinical Trial for the Treatment of Alzheimer’s Disease

March 3, 2022

LEXEO Receives the US FDA’s IND Clearance of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy

LEXEO Receives the US FDA’s IND Clearance of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy

February 17, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us